

## Moxonidine, a Selective Imidazoline- $\alpha_2$ -Adrenergic Receptor Agonist, Produces Spinal Synergistic Antihyperalgesia with Morphine in Nerve-injured Mice

Carolyn A. Fairbanks, Ph.D.,\* H. Oanh Nguyen,† Brent M. Grocholski,† George L. Wilcox, Ph.D.‡

**Background:** Moxonidine, a novel imidazoline- $\alpha_2$ -adrenergic receptor-selective analgesic, was recently identified as antinociceptive but has yet to be evaluated in neuropathic pain models.  $\alpha_2$ -adrenergic receptor-selective analgesics, and high-efficacy opioids, effectively inhibit neuropathic pain behaviors in rodents. In contrast, morphine potency and efficacy decreases in states of neuropathic pain, both in rodents and in humans, but may be restored or enhanced by coadministration of morphine with  $\alpha_2$ -adrenergic receptor-selective analgesics. The current experiments extend the evaluation of opioid-coadjuvant interactions in neuropathic subjects by testing the respective antihyperalgesic interactions of moxonidine and clonidine with morphine in a test of mechanical hyperalgesia.

**Methods:** Nerve-injured mice (Chung model) were spinally administered moxonidine, clonidine, morphine, and the combinations moxonidine-morphine and clonidine-morphine. Hyperalgesia was detected by von Frey monofilament stimulation (3.3 mN) to the hind paws (plantar surface). The ED<sub>50</sub> values were calculated and the interactions tested by isobolographic analysis.

**Results:** In nerve-injured mice, moxonidine, clonidine, and morphine all dose-dependently inhibited mechanical hyperalgesia. Furthermore, the combinations of moxonidine-morphine and clonidine-morphine resulted in substantial leftward

shifts in the dose-response curves compared with those of each agonist administered separately. The calculated ED<sub>50</sub> values of the dose-response curves of these combinations were significantly lower than their corresponding theoretical additive ED<sub>50</sub> values. These results confirmed that both interactions were synergistic.

**Conclusions:** Moxonidine and clonidine both synergize with morphine to inhibit paw withdrawal from nociceptive mechanical stimuli in nerve-injured mice. (Key words: Chronic pain; isobologram; spinally mediated analgesia; synergy.)

MOXONIDINE is a member of the imidazoline- $\alpha_2$ -adrenergic receptor (AR) class of compounds, is a centrally active compound, and is clinically used in Europe to treat hypertension.<sup>1</sup> We recently described a spinal antinociceptive action of moxonidine in two strains of mice.<sup>2</sup> In that study, we demonstrated that the receptor requirement for the spinal antinociception of moxonidine differs dramatically from that of previously studied  $\alpha_2$ -AR agonists. In genetically altered mice,<sup>3</sup> intrathecally administered norepinephrine-, dexmedetomidine- and UK-14,304-mediated analgesia showed a large dependence on  $\alpha_{2A}$ -AR subtype<sup>2,4</sup>; clonidine showed an absolute requirement for activation of the  $\alpha_{2A}$ -AR subtype to produce analgesia.<sup>2</sup> In contrast, spinal antinociception mediated by moxonidine requires some  $\alpha_2$ -AR activation but is not  $\alpha_{2A}$ -AR-dependent.<sup>2</sup> This spinal independence of the  $\alpha_{2A}$ -AR subtype distinguishes moxonidine from clonidine and suggests an analgesic role for either  $\alpha_{2B}$  or  $\alpha_{2C}$  ARs, consistent with *in vitro* evidence indicating that moxonidine is not selective for one  $\alpha_2$ -AR subtype over another ( $\alpha_{2A}$  AR:  $13.0 \pm 4.2$  nM;  $\alpha_{2B}$  AR:  $9.5 \pm 4.1$  nM;  $\alpha_{2C}$  AR:  $15.6 \pm 9.8$  nM).<sup>5</sup> The significance of this observation is underscored by evidence suggesting a requirement for activation of the  $\alpha_{2A}$ -AR subtype to produce sedation.<sup>6</sup> Selective activation of an  $\alpha_2$ -AR subtype other than  $\alpha_{2A}$  AR (e.g.,  $\alpha_{2B}$  or  $\alpha_{2C}$ ) might, therefore, improve  $\alpha_2$ -AR-mediated analgesia by reducing the incidence of sedation. Furthermore, comparisons of the

\* Postdoctoral Fellow, Departments of Pharmacology and Neuroscience.

† Student Laboratory Technician, Department of Pharmacology.

‡ Professor, Departments of Neuroscience and Pharmacology.

Received from the Departments of Pharmacology and Neuroscience, University of Minnesota, Minneapolis, Minnesota. Submitted for publication October 22, 1999. Accepted for publication March 31, 2000. Supported by grant Nos. R01-DA-01933 and R01-DA-04274, and AD-AMHA training grant No. T32A07234 (Dr. Fairbanks), from the National Institute on Drug Abuse, Bethesda, Maryland. Presented at the annual meeting of the American Pain Society, San Diego, California, November 7, 1998.

Address reprint requests to Dr. Wilcox: Departments of Neuroscience and Pharmacology, 6-120 Jackson Hall, 321 Church Street SE, Minneapolis, Minnesota 55455-0217. Address electronic mail to: george@umn.edu

Individual article reprints may be purchased through the Journal Web site, www.anesthesiology.org

analgesic 5profile of spinally administered clonidine ( $\alpha_{2A}$ -AR-dependent) and moxonidine ( $\alpha_{2A}$ -AR-independent) may expand current understanding of the role of  $\alpha_2$ -AR subtypes in spinally mediated analgesia, particularly in light of recent evidence demonstrating distinct localization of  $\alpha_2$ -AR subtypes in spinal cord dorsal horn.<sup>7</sup>

To further characterize moxonidine-mediated analgesia, we also demonstrated spinal moxonidine-morphine and moxonidine-deltorphin II antinociceptive synergism in mice.<sup>8</sup> To expand this characterization, the current study evaluates the effects of spinally administered moxonidine (delivered alone or with morphine) on neuropathic pain behaviors<sup>9</sup> in mice subjected to peripheral nerve injury (Chung model).<sup>10</sup> For comparison with clinically used agents, the current study also characterizes the action of intrathecally administered morphine, clonidine, and their combination in this mouse model of neuropathic pain.

## Materials and Methods

### Animals

Experimental subjects were 25–30-g male Institute of Cancer Research mice (Harlan, Madison, WI). Subjects were housed in groups of 5–10 in a temperature- and humidity-controlled environment. Subjects were maintained on a 12-h light–dark cycle and had free access to food and water. Each animal was used only once. These experiments were approved by the Institutional Animal Care and Use Committee.

### Chemicals

Moxonidine [4-chloro-5-(2imidazolin-2-ylamino)-6-methoxy-2-methylpyrimidine] chloride was a gift from Solvay Pharma (Hannover, Germany) and was dissolved in 1% acetic acid and diluted with acidified saline (pH 3.2–4). All other drugs were dissolved in 0.9% saline. Morphine was a gift from the National Institute on Drug Abuse (Bethesda, MD). Clonidine HCl (2-[2,6-dichloroaniline]-2-imidazoline) was a gift from Boehringer-Ingelheim Ltd. (Ridgefield, CT). All drugs and drug combinations were injected intrathecally by direct lumbar puncture.<sup>11</sup> Briefly, each mouse is gripped firmly by the pelvic girdle. A 30-gauge needle connected to a 50- $\mu$ l Hamilton syringe is lowered at a 30° angle and inserted at the level of the cauda equina. Puncture of the dura is indicated by a reflexive flick of the tail.

### Hyperalgesia Induction: Spinal Nerve Ligation

Hypersensitivity was induced by surgical ligation of the L5 spinal nerve in mice.<sup>10</sup> Mice were placed in an enclosed chamber and anesthetized by halothane and placed in a prone position before any surgery. When the animal was unresponsive to paw pinch, it was removed from the chamber, shaved from below the iliac crest to approximately halfway to the shoulders, and fitted with a facemask delivering 2 or 3% halothane, which was continuously administered to the animal throughout the surgery. Betadine was applied to the shaved area before the incision. The left paraspinal muscle was separated from the spinous processes at the L4–S2 levels and removed. Removal of this muscle does not impair mobility of the animal after surgery. A Mini-Goldstein retractor (Fine Science Tools No. 17002-02, Foster City, CA) with a 1-cm maximum spread was then inserted into the incision at the level of the iliac crest. Further removal of muscle and tissue permitted visualization of the L6 transverse process and the rostral tip of the sacrum. The L6 transverse process was then removed with use of an S&W fine forceps with a tip dimension of 0.3  $\times$  0.25 mm (Fine Science Tools No. 00108-11). Removal of the process permitted visual identification of the L4–L5 spinal nerves. The L5 spinal nerve was tightly tied (ligated) with 6-0 silk thread distal to the dorsal root and proximal to the confluence of spinal nerves L4 and L5. After hemostasis was confirmed, the wound was sutured with 3-0 silk thread, and the skin was closed with sterile wound clips. The animal was then placed in a moderately heated oxygen-enriched plastic enclosure to facilitate recovery. The animals were fully mobile within 30 min of cessation of anesthetic. As a control, in a separate group of animals, a sham surgery identical to the aforementioned one (but without nerve ligation) was performed.

### Nociceptive Testing: Tactile Sensitivity

Nociception was evaluated by responsiveness to multiple applications (10 per hind paw) of a single von Frey filament to the plantar surface of each hind paw. When the stimulus is of sufficient force, the mouse will lick, withdraw, or shake the paw; this action represents the behavioral end point. In nerve-injured mice, a von Frey filament (#3.61) exerting 3.3 mN of force elicited  $66 \pm 1.3\%$  responsiveness [(number of withdrawals/10)  $\times$  100] on the paw ipsilateral to the injury. This level of response is sufficient to test compounds for dose-dependent inhibition of the response to mechanical stimulation.

## MORPHINE-MOXONIDINE SYNERGY IN NERVE-INJURED MICE

**Table 1. I5-ligated Mice, Affected Paw: Summary of Moxonidine-Morphine Spinal Antihyperalgesic Synergy**

Agonist (pmol, i.t.)	ED <sub>50</sub> Morphine (95% CL)	ED <sub>50</sub> Moxonidine (95% CL)
Single agonist	64 (30–135)	14 (4.1–50)
Morphine + moxonidine (4:1 ratio)		
Observed combination	1.2 (0.7–1.7)*	0.3 (0.17–0.43)*
Theoretical additive	30 (7.2–54)	7.6 (1.8–13)

\* Significant difference from theoretical additive by Student *t* test (*P* < 0.05).

*Inhibition of Tactile Sensitivity*

Varying doses of moxonidine, morphine, or clonidine, or combinations thereof, were administered to test for inhibition of tactile sensitivity. Percent inhibition was determined relative to the mean number of paw withdrawals elicited by force and according to the following equation:

% Inhibition = (no. of paw withdrawals predrug – no. of paw withdrawals postdrug)/no. of paw withdrawals predrug

Each mouse served as its own control. The ED<sub>50</sub> values (the dose calculated to produce 50% inhibition) and 95% confidence limits were calculated according to the method of Tallarida and Murray.<sup>12</sup> To test for the antihyperalgesic effects of moxonidine and morphine over time, groups of mice injected with various doses of drug or acidified saline were concurrently tested at 5, 10, 30, 60, 90, and 120 min after intrathecal injection. ED<sub>50</sub> values were calculated at the 10-min time point. To test for drug interactions, a separate group of animals (*n* = 126) was subjected to surgery within the same week. All behavioral testing was conducted the following week on the corresponding day 8 at 10 min after drug injection. New dose-response curves were generated for each drug given alone (morphine, moxonidine, clonidine) or given in combination (morphine-moxonidine, morphine-clonidine), and corresponding ED<sub>50</sub> values were calculated (*n* = 4–8 mice/dose).

*Statistical Analysis*

Data describing antihyperalgesia are expressed as means of percent inhibition with SEM. Student *t* test

comparisons were made between responses of the left and right hind paws of all animals before surgery, and left and right hind paws of nerve-injured, sham, and naive animals after surgery (*P* < 0.05). The comparison between the left (injured) hind paws of nerve-injured and the left hind paws of sham-operated and naive animals after surgery was also evaluated by analysis of variance. Drug potency comparisons are based on the calculated ED<sub>50</sub> values for the dose-response curve of each drug or combination of drugs.

*Isobolographic Analysis*

To test for drug interactions, isobolographic analysis was applied.<sup>12,13</sup> When testing an interaction between two drugs given in combination for synergy, additivity or subadditivity, a theoretical additive ED<sub>50</sub> value is calculated for the combination based on the dose-response curves of each drug administered separately. This theoretical value is then compared by a *t* test (*P* < 0.05) with the observed experimental ED<sub>50</sub> value for the combination. These values are based on total dose of both drugs, *i.e.*, the dose of clonidine or moxonidine plus the dose of morphine. For the purpose of comparison to the drug doses administered separately, we separated the clonidine or moxonidine and morphine components of the observed and theoretical ED<sub>50</sub> values; these are presented in tables 1 and 2. An interaction is considered synergistic if the observed ED<sub>50</sub> value is significantly less (*P* < 0.05) than the calculated theoretical additive ED<sub>50</sub> value.<sup>12,13</sup> Additivity is indicated when the theoretical and experimental ED<sub>50</sub> values do not differ.

**Table 2. I5-ligated Mice, Affected Paw: Summary of Clonidine-Morphine Spinal Antihyperalgesic Synergy**

Agonist (pmol, i.t.)	ED <sub>50</sub> Morphine (95% CL)	ED <sub>50</sub> Clonidine (95% CL)
Single agonist	64 (30–135)	4,600 (1,800–11,000)
Morphine + clonidine (1:44 ratio)		
Observed combination	4.0 (0.4–7.6)*	174 (16–332)*
Theoretical additive	40 (17–63)	1,740 (732–2,748)

\* Significant difference from theoretical additive by Student *t* test (*P* < 0.05).

## Results

### Induction of Hyperalgesia

No difference was observed in baseline percent response to a force of 3.3 mN (von Frey filament #3.61, our calibration) between the left (mean =  $27 \pm 1.8\%$ ,  $n = 142$ ) and right hind paws (mean =  $27 \pm 1.8\%$ ,  $n = 142$ ;  $P > 0.05$ , Student unpaired  $t$  test) of mice before injury. On day 8 after surgery, a substantial increase in responsiveness was observed for both hind paws (fig. 1), and the increase was significantly greater for the left hind paw (ipsilateral to the ligation, mean =  $66 \pm 1.3\%$ ,  $n = 126$ ) than for the right hind paw (contralateral to the ligation: mean =  $48 \pm 1.8\%$ ,  $n = 126$ ;  $P < 0.01$ , Student unpaired  $t$  test; Fig. 1). This small increase in sensitivity on the contralateral side is consistent with previous reports of contralateral effects after nerve injury.<sup>14</sup> Both of these responses were substantially greater than that of either hind paw of the control animals; controls included those mice that received sham surgery (left hind paw: mean =  $35 \pm 15\%$ ,  $n = 6$ ; right hind paw, mean =  $33 \pm 8.4\%$ ,  $n = 6$ ) and naive mice (left hind paw: mean =  $30 \pm 6.2\%$ ,  $n = 9$ ; right hind paw: mean =  $33 \pm 9.9\%$ ,  $n = 9$ ). These differences show that the L5 spinal nerve ligation surgery is sufficient to produce hyperalgesia in the hind paw ipsilateral to the injury.

### Moxonidine-mediated Antihyperalgesia

Moxonidine inhibition of mechanical hyperalgesia is represented in figure 2 and expressed as percent inhibition of the percent response to mechanical stimulation. Moxonidine at 0.1- and 1-nmol doses significantly attenuated the hyperalgesia for 10 and 90 min, respectively, whereas 0.03 nmol moxonidine and acidified saline had minimal effect on hyperalgesia. Moxonidine appeared to have a longer duration of action in the ipsilateral hind paw relative to the contralateral hind paw. The calculated  $ED_{50}$  values of moxonidine at the 10-min time point were comparable between the ipsilateral and contralateral hind paws (ipsilateral: 0.12 nmol, 0.058–0.24; contralateral: 0.12 nmol, 0.037–0.39). We evaluated the doses at the 10-min time point because that time represents the peak analgesic effect at a time most likely involving a selectively spinal effect.<sup>11</sup>

### Morphine-mediated Antihyperalgesia

Morphine inhibition of mechanical hyperalgesia is represented in figure 3. Morphine at 3- and 10-nmol doses significantly attenuated the hyperalgesia for the duration of the test period (120 min) in both the ipsilateral and




Fig. 1. In nerve-injured mice, a substantial increase in response was observed for both hind paws; the increase was significantly greater for the paw ipsilateral to the ligation (closed triangles) than for the paw contralateral to the ligation (open diamonds;  $P < 0.01$ , Student unpaired  $t$  test). Control animals include sham-operated mice (ipsilateral paw, closed circles; contralateral paw, open circles) and naive mice (left paw, closed squares; right paw, open squares). \*Indicates statistical significance (ANOVA,  $P < 0.05$ ).

contralateral hind paws. The calculated  $ED_{50}$  values for morphine at the 10-min time point were comparable between the ipsilateral and contralateral hind paws (ipsilateral: 1.1 nmol, 0.5–2.4; contralateral: 2.4 nmol, 0.88–6.4, not significantly different). Morphine appeared to have comparable duration of action in both the ipsilateral and contralateral hind paws.

### Moxonidine-Morphine Synergy (Hind Paw Ipsilateral to the Injury)


Intrathecal administered moxonidine ( $ED_{50}$ : 1 pmol, 4.1–50) and morphine ( $ED_{50}$ : 64 pmol, 30–135) both inhibited mechanical hyperalgesia (fig. 4A). Based on these  $ED_{50}$  values, the moxonidine-morphine equi-effective dose ratio used was 1:4. Combination of moxonidine and morphine at this dose ratio resulted in significant leftward shifts in the dose-response curves (*i.e.*, increased potency) compared with those of each agonist administered separately (fig. 4A and table 1). The coadministration of moxonidine-morphine combinations in mice resulted in antihyperalgesic dose-response curves with  $ED_{50}$  values significantly less than the calculated theoretical additive values (fig. 4B and table 1). This result indicates a synergistic interaction.

### Morphine-Clonidine Synergy (Hind Paw Ipsilateral to the Injury)

Intrathecal administered clonidine ( $ED_{50}$ : 4,600 pmol, 1,800–11,000) and morphine ( $ED_{50}$ : 64 pmol,



Fig. 2. Moxonidine dose-dependently attenuated mechanical hyperalgesia. (A) Ipsilateral (injured) paw. Moxonidine at 1-nmol (squares) and 0.1-nmol (circles) doses significantly attenuated mechanical hyperalgesia for 90 and 10 min, respectively, whereas 0.03 nmol (triangles) moxonidine moderately decreased hyperalgesia. (B) Contralateral paw. Moxonidine at 1-nmol (squares) and 0.1-nmol (circles) doses significantly attenuated the hyperalgesia for 60 and 10 min, respectively, whereas 0.03 nmol (triangles) moxonidine moderately decreased hyperalgesia. For both (A) and (B) statistical significance of the dose-dependent effect of moxonidine at the 10–60-min time points was shown by repeated-measures analysis of variance followed by Bonferroni *post hoc* test. A dose of 0.01 nmol (data not shown) did not have an effect greater than that of acidified saline (diamonds), which had minimal effect on hyperalgesia. Before administration of moxonidine, confirmation of induction of hyperalgesia (similar to that shown in fig. 1) was conducted for this time-course study (data not shown).



30–135) both inhibited mechanical hyperalgesia (fig. 5A). The morphine-clonidine equi-effective dose ratio used was 1:44. Combination of clonidine and morphine at this dose ratio resulted in significant leftward shifts in the dose-response curves compared with those of each agonist administered separately (fig. 5A and table 2). The coadministration of clonidine-morphine combinations in mice resulted in antihyperalgesic dose-response curves with ED<sub>50</sub> values significantly less than the calculated theoretical additive values (fig. 5B and table 2). This result confirms a synergistic interaction.

#### Side Effects


We did not detect obvious motor or sedative side effects with use of these doses of moxonidine, morphine, clonidine, and the combinations; however, we have not conducted systematic evaluation of these effects through use of the rotorod or righting reflex assays.

#### Discussion

The current study introduces a new antihyperalgesic agent: the imidazoline- $\alpha_2$ -AR agonist moxonidine. The study also shows that both the imidazoline- $\alpha_2$ -AR agonists moxonidine and clonidine combined with morphine produce spinal antihyperalgesic synergy in nerve-injured mice.

The ability of  $\alpha_2$ -AR agonists to produce antihyperalgesia in the mechanical von Frey monofilament stimulation test has been previously observed.<sup>15,16</sup> Spinal administration of dexmedetomidine, oxymetazoline, and guanfacine resulted in a dose-dependent reversal of the hyperalgesia induced by L5-L6 spinal nerve ligation in rats.<sup>15,16</sup> We have now shown that, like these other  $\alpha_2$ -AR agonists, moxonidine also dose-dependently decreased hyperalgesic paw withdrawals with a potency comparable to that of morphine and greater than that of

Fig. 3. Morphine dose-dependently attenuated mechanical hyperalgesia. (A) Ipsilateral (injured) paw. Morphine at 10-nmol (squares) and 3-nmol (circles) doses significantly attenuated the hyperalgesia for the duration of the study (120 min); 1 nmol (triangles) morphine moderately attenuated hyperalgesia. (B) Contralateral paw. Morphine at 10-nmol (squares) and 3-nmol (circles) doses significantly attenuated the hyperalgesia for the duration of the study (120 min); 1 nmol (triangles) morphine moderately attenuated hyperalgesia. Intrathecal administration of 0.3 nmol (diamonds) morphine had minimal effect on hyperalgesia. The significance of the dose-dependent effect of morphine was shown by repeated-measures analysis of variance followed by Bonferroni *post hoc* test. Before administration of morphine, confirmation of induction of hyperalgesia (similar to that shown in fig. 1) was conducted for this time-course study (data not shown).






Fig. 4. Moxonidine and morphine synergize to alleviate mechanical hyperalgesia. Dose-response curves for moxonidine, morphine, and moxonidine-morphine administered intrathecally separately and in combination. (A) Dose-response curves of the spinal antihyperalgesic effect of moxonidine (open circles, solid lines, ED<sub>50</sub>: 14 pmol, 4.1–50), morphine (open triangles, dashed lines, ED<sub>50</sub>: 64 pmol, 30–135), moxonidine in the presence of morphine (closed circles, solid lines, ED<sub>50</sub>: 0.3 pmol, 0.17–0.43), and morphine in the presence of moxonidine (closed triangles, dashed lines, ED<sub>50</sub>: 1.1 pmol, 0.7–1.7). (B) Isobolographic representation of the antihyperalgesic (percent inhibition) effect of the combination of moxonidine-morphine in nerve-injured mice. Drug interactions may be illustrated through construction of such isobolograms. The ED<sub>50</sub> values of clonidine or moxonidine and morphine are respectively plotted as the y- and x-axis intercepts. The thicker lines directed from each ED<sub>50</sub> value toward zero represent the respective lower confidence limits of each ED<sub>50</sub> value. The straight line connecting these two points is the theoretical additive line. The open circle that lies on or near the theoretical additive line represents the calculated theoretical ED<sub>50</sub> value of the combination where the interaction is additive. The closed circle represents the experimentally observed ED<sub>50</sub> value of the combination of clonidine-morphine. If the interaction is synergistic, the closed circle will be plotted significantly below the theoretical additive line and outside the lower confidence limit of ED<sub>50</sub> values of clonidine and morphine. In this isobologram, the ED<sub>50</sub> value of the combination of clonidine-morphine is significantly lower than that of the theoretical additive ED<sub>50</sub> value and is synergistic.

axis intercepts. The thicker lines directed from each ED<sub>50</sub> value toward zero represent the respective lower confidence limits of each ED<sub>50</sub> value. The straight line connecting these two points is the theoretical additive line. The open circle that lies on or near the theoretical additive line represents the calculated theoretical ED<sub>50</sub> value of the combination where the interaction is additive. The closed circle represents the experimentally observed ED<sub>50</sub> value of the combination of clonidine-morphine. If the interaction is synergistic, the closed circle will be plotted significantly below the theoretical additive line and outside the lower confidence limit of ED<sub>50</sub> values of clonidine and morphine. In this isobologram, the ED<sub>50</sub> value of the combination of clonidine-morphine is significantly lower than that of the theoretical additive ED<sub>50</sub> value and is synergistic.

clonidine. Morphine remains the standard with which other analgesics are compared, and clonidine is the prototypic analgesic  $\alpha_2$ -AR agonist. Our comparisons of moxonidine to clonidine and morphine in neuropathic pain in mice suggest that the performance of moxonidine in humans as an analgesic and antihyperalgesic agent may compare favorably with that of morphine and clonidine.

The ability of opioid receptor agonists to inhibit hyperalgesia in nerve-injured animals has also been previously evaluated. Two studies<sup>17,18</sup> report that systemically and intracerebroventricularly (but not intrathecally) administered morphine inhibited mechanical hyperalgesia in nerve-injured rats. Additionally, intrathecally administered deltorphin II, a  $\delta$  opioid receptor-selective agonist, showed decreased antihyperalgesic potency and efficacy in nerve-injured rats.<sup>19</sup> Other studies with use of thermal stimulation of the tail as the nociceptive stimulus showed that the intrathecal antinociceptive potency of morphine was decreased approximately twofold<sup>20</sup> or fourfold<sup>21</sup> in the nerve-injured rats relative to their sham-operated controls. Collectively, these data paralleled the clinical observations that neuropathic pain may be less sensitive to opioids than is nociceptive pain.<sup>22–26</sup>


However, there remains disagreement in the clinical literature over opioid resistance in patients with neuro-

pathic pain.<sup>27,28</sup> Some reports have shown success with use of opioids to treat neuropathic pain.<sup>27–30</sup> Opioids delivered spinally have been shown to be effective in human patients with neuropathic pain.<sup>31–33</sup> Consistent with this clinical experience, at least one study showed that the higher efficacy  $\mu$  opioid receptor-selective agonist, [D-al<sub>2</sub>(2),N-MePhe(4),Gly-ol(5)] enkephalin (DAMGO), produced full dose-related antihyperalgesia when given intrathecally to nerve-injured rats.<sup>19</sup> Additionally, the intrathecally administered combinations of morphine-deltorphin<sup>19</sup> and morphine-clonidine<sup>20</sup> produced antihyperalgesia and antinociceptive synergy, respectively, in nerve-injured rats.

Unlike the comparable rat studies,<sup>17,18</sup> we observed that intrathecal morphine produces antihyperalgesia in nerve-injured mice at doses comparable to those that are effective in sham-operated and naive controls (data not shown). Furthermore, we observed that morphine synergizes with other antihyperalgesic agents in nerve-injured mice, consistent with other studies showing morphine-coadjuvant synergy (morphine-deltorphin,<sup>19</sup> morphine-clonidine<sup>20</sup>) in nerve-injured rat. Retention of opioid sensitivity during conditions of neuropathic pain agrees with other clinical reports,<sup>28,34,35</sup> that opioids are effective as therapeutic agents for neuropathic pain, albeit with higher dose and/or coadjuvant requirements.

## MORPHINE-MOXONIDINE SYNERGY IN NERVE-INJURED MICE

Fig. 5. Clonidine and morphine synergize to alleviate mechanical hyperalgesia. Dose-response curves for clonidine, morphine, and clonidine-morphine administered intrathecally separately and in combination. (A) Dose-response curves of the spinal antihyperalgesic effect of clonidine (open circles, solid lines,  $ED_{50}$ : 4,600 pmol, 1,800–11,000), morphine (open triangles, dashed lines,  $ED_{50}$ : 64 pmol, 30–135), clonidine in the presence of morphine (closed circles, solid lines,  $ED_{50}$ : 174 pmol, 16–332), and morphine in the presence of clonidine (closed triangles, dashed lines,  $ED_{50}$ : 4.0 pmol, 0.4–7.6). (B) Isobolographic representation of the antihyperalgesic (percent inhibition) effect of the combination of clonidine-morphine in nerve-injured mice. In this isobologram, the  $ED_{50}$  value of the combination of clonidine-morphine is significantly lower than that of theoretical additive  $ED_{50}$  value and is synergistic.



Intrathecal coadministration of morphine with moxonidine produced a synergistic antihyperalgesic effect. The observation of moxonidine-morphine synergy concurs with our previous study that showed antinociceptive synergy between intrathecally coadministered moxonidine and morphine.<sup>8</sup> This observation shows that the moxonidine-morphine combination alleviates neuropathic pain responses arising from nerve injury.

Originally, we expected that the morphine-clonidine interaction would not be synergistic in neuropathic mice based on three previous observations: (1) clonidine-mediated spinal analgesia requires the  $\alpha_{2A}$  AR in mice<sup>2</sup>; (2)  $\alpha_{2A}$ -AR immunoreactivity decreased in rat spinal cord dorsal horn after nerve injury<sup>36</sup>; and (3) clonidine antinociceptive effectiveness decreased in nerve-injured rats.<sup>20</sup> However, the current study shows that the clonidine-morphine combination produces antihyperalgesic synergy in nerve-injured mice. Similarly, despite decreases in effectiveness of both drugs when given alone, the clonidine-morphine combination produced antinociceptive synergy in nerve-injured rats<sup>20</sup>; these results suggest that, despite decreases in  $\alpha_{2A}$ -AR immunoreactivity in rat dorsal horn after nerve-injury, sufficient receptor numbers remain functional to participate in this interaction with morphine. Recent evidence provides support for this assertion by showing increased  $\alpha_{2A}$ -AR mRNA<sup>37</sup> and  $\alpha_{2A}$ -AR immunoreactivity<sup>38</sup> in dorsal root ganglia of rats subjected to sciatic nerve transections. These results in dorsal root ganglia together with a previous report<sup>36</sup> raise the possibility of altered splicing or trafficking of  $\alpha_{2A}$  AR in the neuropathic state. Alternatively, nerve

injury may unmask a latent clonidine effect at upregulated  $\alpha_{2C}$  AR.<sup>36</sup> This second possibility is supported by *in vitro* studies that indicate that clonidine shows comparable affinity for human  $\alpha_{2A}$ - and  $\alpha_{2C}$ -AR subtypes.<sup>5</sup> Regardless, the current data support the use of clonidine as a coadjuvant for morphine for the treatment of neuropathic pain.

In summary, the current results show that both moxonidine and clonidine produce spinal antihyperalgesic synergy with morphine in nerve-injured mice. These results concur with previous evaluations of adrenergic agonists in neuropathic pain<sup>15,16</sup> and of morphine-clonidine interactions in normal rodents<sup>39–41</sup> and nerve-injured rats.<sup>20</sup> This is the first study to show an antihyperalgesic property of the imidazoline- $\alpha_2$ -AR agonist moxonidine. It is noteworthy that prior clinical trials of systemically administered moxonidine as an antihypertensive agent show that moxonidine is well-tolerated.<sup>42–46</sup> Furthermore, moxonidine presents an improved side-effect profile over clonidine in terms of reduced sedation and dry mouth,<sup>42,43</sup> rebound withdrawal syndrome,<sup>1,45,47</sup> and hypotensive effects in normotensive subjects.<sup>48</sup> The data presented here would predict that moxonidine may prove effective as a spinal antihyperalgesic agent or coadjuvant to morphine for the treatment of neuropathic pain in humans.

The authors thank Drs. Jin Mo Chung and Seo Lee for instruction in the spinal nerve ligation method, Dr. Laura S. Stone for helpful discussions, and Dr. Dieter Ziegler and Solvay Pharma for the gift of moxonidine.

## References

1. Ziegler D, Haxhiu MA, Kaan EC, Papp JG, Ernsberger P: Pharmacology of moxonidine, an I1-imidazoline receptor agonist. *J Cardiovasc Pharmacol* 1996; 27:S26-37
2. Fairbanks CA, Wilcox GL: Moxonidine, an  $\alpha_2$  adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice. *J Pharmacol Exp Ther* 1999; 290:403-12
3. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE: Central hypotensive effects of the  $\alpha_{2A}$ -adrenergic receptor subtype. *Science* 1996; 273:801-3
4. Stone LS, Macmillan L, Kitto KF, Limbird L, Wilcox GL: The  $\alpha_{2A}$ -adrenergic receptor subtype mediates spinal analgesia evoked by  $\alpha_2$  agonists and is necessary for spinal adrenergic/opioid synergy. *J Neurosci* 1997; 17:7157-65
5. Piletz JE, Zhu H, Chikkala DN: Comparison of ligand binding affinities at human I-1-imidazoline binding sites and the high affinity state of  $\alpha$ -2 adrenoceptor subtypes. *J Pharmacol Exp Ther* 1996; 279:694-702
6. Lakhani PP, Macmillan LB, Guo TZ, Mccool BA, Lovinger DM, Maze M, Limbird LE: Substitution of a mutant  $\alpha(2a)$ -adrenergic receptor via hit and run gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. *Proc Natl Acad Sci U S A* 1997; 94:9950-5
7. Stone LS, Broberger C, Vulchanova L, Wilcox GL, Hokfelt T, Riedl MS, Elde R: Differential distribution of  $\alpha$ 2A and  $\alpha$ 2C adrenergic receptor immunoreactivity in the rat spinal cord. *J Neurosci* 1998; 18:5928-37
8. Fairbanks CA, Posthumus IJ, Kitto KF, Stone LS, Wilcox GL: Moxonidine, a selective imidazoline/ $\alpha_2$  adrenergic receptor agonist, synergizes with morphine and deltorphin II to inhibit substance P-induced behavior in mice. *Pain* 2000; 84:13-20
9. Kim SH, Chung JM: An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. *Pain* 1992; 50:355-63
10. Mogil JS, Wilson SG, Bon K, Lee SE, Chung K, Raber P, Pieper JO, Hain HS, Belknap JK, Hubert L, Elmer GI, Chung JM, Devor M: Heritability of nociception I: Responses of 11 inbred mouse strains on 12 measures of nociception. *Pain* 1999; 80:67-82
11. Hylden JLK, Wilcox GL: Intrathecal morphine in mice: A new technique. *Eur J Pharmacol* 1980; 67:313-6
12. Tallarida RJ, Murray RB: Manual of Pharmacological Calculations with Computer Programs. New York, Springer Verlag, 1987, pp 26-31
13. Tallarida RJ: Statistical analysis of drug combinations for synergism [published erratum appears in *Pain* 1993; 53:365]. *Pain* 1992; 49:93-7
14. Koltzenburg M, Wall PD, McMahon SB: Does the right side know what the left is doing? *Trends Neurosci* 1999; 22:122-7
15. Yaksh TL, Pogrel JW, Lee YW, Chaplan SR: Reversal of nerve ligation-induced allodynia by spinal  $\alpha$ -2 adrenoceptor agonists. *J Pharmacol Exp Ther* 1995; 272:207-14
16. Poree LR, Guo TZ, Kingery WS, Maze M: The analgesic potency of dexmedetomidine is enhanced after nerve injury: A possible role for peripheral  $\alpha$ -2 adrenoceptors. *Anesth Analg* 1998; 87:941-8
17. Lee YW, Chaplan SR, Yaksh TL: Systemic and supraspinal, but not spinal, opiates suppress allodynia in a rat neuropathic pain model. *Neurosci Lett* 1995; 199:111-4
18. Bian D, Nichols ML, Ossipov MH, Lai J, Porreca F: Characterization of the antiallodynic efficacy of morphine in a model of neuropathic pain in rats. *Neuroreport* 1995; 6:1981-4
19. Nichols ML, Bian D, Ossipov MH, Lai J, Porreca F: Regulation of morphine antiallodynic efficacy by cholecystokinin in a model of neuropathic pain in rats. *J Pharmacol Exp Ther* 1995; 275:1339-45
20. Ossipov MH, Lopez Y, Bian D, Nichols ML, Porreca F: Synergistic antinociceptive interactions of morphine and clonidine in rats with nerve-ligation injury. *ANESTHESIOLOGY* 1997; 86:1-9
21. Ossipov MH, Lopez Y, Nichols ML, Bian D, Porreca F: Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury. *Neurosci Lett* 1995; 199:83-6
22. Arner S, Meyerson BA: Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. *Pain* 1988; 33:11-23
23. Coombs DW, Maurer LH, Saunders RL, Gaylor M: Outcomes and complications of continuous intraspinal narcotic analgesia for cancer pain control. *J Clin Oncol* 1984; 2:1414-20
24. Siddall PJ, Gray M, Rutkowski S, Cousins MJ: Intrathecal morphine and clonidine in the management of spinal cord injury pain: A case report. *Pain* 1994; 59:147-8
25. Yoshioka H, Tsuneto S, Kashiwagi T: Pain control with morphine for vertebral metastases and sciatica in advanced cancer patients. *J Palliative Care* 1994; 10:10-3
26. Cherny NI, Thaler HT, Friedlander-Klar H, Lapin J, Foley KM, Houde R, Portenoy RK: Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: A combined analysis of controlled, single-dose studies. *Neurology* 1994; 44:857-61
27. McQuay HJ, Jadad AR, Carroll D, Faura C, Glynn CJ, Moore RA, Liu Y: Opioid sensitivity of chronic pain: A patient-controlled analgesia method. *Anaesthesia* 1992; 47:757-67
28. Jadad AR, Carroll D, Glynn CJ, Moore RA, McQuay HJ: Morphine responsiveness of chronic pain: Double-blind randomised crossover study with patient-controlled analgesia. *Lancet* 1992; 339:1367-71
29. Zenz M, Strumpf M, Tryba M: Long-term oral opioid therapy in patients with chronic nonmalignant pain. *J Pain Symptom Manage* 1992; 7:69-77
30. Makin MK, Ellershaw JE: Substitution of another opioid for morphine: Methadone can be used to manage neuropathic pain related to cancer. *BMJ* 1998; 317:81
31. Wen YR, Hou WY, Chen YA, Hsieh CY, Sun WZ: Intrathecal morphine for neuropathic pain in a pregnant cancer patient. *J Formosan Med Assoc* 1996; 95:252-4
32. Iacono RP, Boswell MV, Neumann M: Deafferentation pain exacerbated by subarachnoid lidocaine and relieved by subarachnoid morphine: Case report. *Reg Anesth* 1994; 19:212-5
33. Van Melkebeke S, Wostyn L, Gellens P, Camu F: Continuous cervical intrathecal administration of morphine with a new infusion pump, the Anschutz IP 35.1: A case report. *Acta Anaesth Belg* 1995; 46:87-91
34. Portenoy RK, Foley KM: Chronic use of opioid analgesics in non-malignant pain: Report of 38 cases. *Pain* 1986; 25:171-86
35. Portenoy RK, Foley KM, Inturrisi CE: The nature of opioid responsiveness and its implications for neuropathic pain: New hypotheses derived from studies of opioid infusions [see comments]. *Pain* 1990; 43:273-86
36. Stone LS, Vulchanova L, Riedl MS, Wang J, Williams FG, Wilcox GL, Elde R: Effects of peripheral nerve injury on  $\alpha$ -2a and  $\alpha$ -2c adrenergic receptor immunoreactivity in the rat spinal cord. *Neuroscience* 1999; 93:1399-1407
37. Shi TJS, Winzer-Serhan U, Leslie F, Hokfelt T: Distribution and



## MORPHINE-MOXONIDINE SYNERGY IN NERVE-INJURED MICE

regulation of  $\alpha_2$ -adrenoceptors in rat dorsal root ganglia. *Pain* 2000; 84:319-30

38. Birdier LA, Perl ER: Expression of  $\alpha_2$ -adrenergic receptors in rat primary afferent neurones after peripheral nerve injury or inflammation. *J Physiol* 1999; 515:533-42

39. Ossipov M, Lozito R, Messineo E, Green J, Harris S, Lloyd P: Spinal antinociceptive synergy between clonidine and morphine, U69593, and DPDPE: Isobolographic analysis. *Life Sci* 1990; 47:PL71-6

40. Roerig S, Lei S, Kitto K, Hylden JLK, Wilcox GL: Spinal interactions between opioid and noradrenergic agonists in mice: Multiplicity involves  $\delta$  and  $\alpha_2$  receptors. *J Pharmacol Exp Ther* 1992; 262:365-74

41. Fairbanks CA, Wilcox GL: Spinal antinociceptive synergism between morphine and clonidine persists in mice made acutely or chronically tolerant to morphine. *J Pharmacol Exp Ther* 1999; 288:1107-16

42. Plänitz V: Crossover comparison of moxonidine and clonidine in mild to moderate hypertension. *Eur J Clin Pharmacol* 1984; 27:147-52

43. Plänitz V: Intraindividual comparison of moxonidine and prazosin in hypertensive patients. *Eur J Clin Pharmacol* 1986; 29:645-50

44. Ollivier JP, Christen MO: 11-imidazoline-receptor agonists in the treatment of hypertension: An appraisal of clinical experience. *J Cardiovasc Pharmacol* 1994; 24:S39-48

45. Kraft K, Vetter H: Twenty-four-hour blood pressure profiles in patients with mild-to-moderate hypertension: Moxonidine versus captopril. *J Cardiovasc Pharmacol* 1994; 24:S29-33

46. Küppers HE, Jager BA, Luszick JH, Grave MA, Hughes PR, Kaan EC: Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. *J Hypertens* 1997; 15:93-7

47. Webster J, Koch HF: Aspects of tolerability of centrally acting antihypertensive drugs. *J Cardiovasc Pharmacol* 1996; 27:S49-54

48. Macphée GJ, Howie CA, Elliott HL, Reid JL: A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects. *Br J Clin Pharmacol* 1992; 33:261-7